Area of research
Immunology · Oncology
Research interest
Dr. Vignali’s research focuses on gaining a better understanding of the inhibitory mechanisms, including inhibitory receptors and regulatory T cells, that limit anti-tumor immunity in cancer patients. I also have discovery-based programs aimed at identifying novel targets for therapeutic intervention. I am also working with UPCI scientists and clinicians to facilitate the translation of novel therapeutic modalities with a focus on immunologically impacted solid tumors (primarily head and neck, melanoma, lung, pancreatic cancer). My UPCI leadership efforts are directed toward providing a bridge between basic and transitional cancer immunology. Lastly, I also work extensively with large and start-up biopharmaceutical companies to bring novel therapeutics to the clinic.
Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies
Mammary intraepithelial lymphocytes and intestinal inputs shape T cell dynamics in lactogenesis
Aplp1 interacts with Lag3 to facilitate transmission of pathologic α-synuclein
Ebi3 Binding to IFN-γ and IL-10 Limits Their Function
Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment
The GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation
Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer
Metabolic support of tumour-infiltrating regulatory T cells by lactic acid
Interferon-γ: teammate or opponent in the tumour microenvironment?
B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma
Interleukin-35: Structure, Function and Its Impact on Immune-Related Diseases
Inhibitory signaling sustains a distinct early memory CD8 <sup>+</sup> T cell precursor that is resistant to DNA damage
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity
Competition for Active TGFβ Cytokine Allows for Selective Retention of Antigen-Specific Tissue- Resident Memory T Cells in the Epidermal Niche
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding
Understanding adverse events of immunotherapy: A mechanistic perspective
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion
Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor
Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ
A Bayesian mixture model for clustering droplet-based single-cell transcriptomic data from population studies
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
BAMM-SC: A Bayesian mixture model for clustering droplet-based single cell transcriptomic data from population studies
<scp>LAG</scp>3 (<scp>CD</scp>223) as a cancer immunotherapy target
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Globule Leukocytes and Other Mast Cells in the Mouse Intestine
Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3